Deal watch: Anti-IL-5 antibody attracts Cephalon to agree option for Ception acquisition.
D000328:Adult; D000911:Antibodies, Monoclonal / Q000191:economics* / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy / Q000276:immunology; D002648:Child; D002986:Clinical Trials as Topic; D004345:Drug Industry / Q000191:economics / Q000458:organization & administration*; D004802:Eosinophilia / Q000188:drug therapy / Q000276:immunology; D004941:Esophagitis / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D015848:Interleukin-5 / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015848:Interleukin-5; C515492:reslizumab